Hikma Pharmaceuticals PLC

Common Name
Hikma Pharmaceuticals
Country
United Kingdom
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9,500
Ticker
HIK
Exchange
LONDON STOCK EXCHANGE
Description
Hikma Pharmaceuticals PLC is a leading multinational pharmaceutical company that specializes in manufacturing and marketing a wide range of generic and in-licensed pharmaceutical products. Established...

Hikma Pharmaceuticals's Climate Target Data Preview

As of 2023, Hikma Pharmaceuticals has disclosed 1 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 absolute reduction target, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Hikma Pharmaceuticals ’s climate strategy, ambition level, and alignment with global decarbonization goals.

Target TypeScope of TargetUnitTargetTarget Year
Absolute-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e)
Copy restricted. Please purchase to unlock this data.
2030

This table provides a simplified preview of selected climate targets data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.

Insights into Hikma Pharmaceuticals's Greenhouse Gas Emissions Pathways

As of 2023, Hikma Pharmaceuticals has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions.

Does Hikma Pharmaceuticals have a target to reduce the emissions from its operations?

As of 2023, Hikma Pharmaceuticals has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.

Hikma Pharmaceuticals's most ambitious operational target is to reduce these emissions by 25% by 2030, compared to a baseline of 144,899 Metric Tonnes of CO2 equivalent (mtCO2e) in 2020.

As of 2023, Hikma Pharmaceuticals is ahead of schedule on its operational emissions reduction target, having achieved 58.44% of the planned reduction.

Hikma Pharmaceuticals's Operational (Scope 1+2) Emissions Pathway

202020232030040 k80 k120 k160 kBaselineCurrent (-15%)
Want Full Access to Hikma Pharmaceuticals's Climate Targets Dataset?
Sign Up